Benign Prostatic Hyperplasia Drug Information

Antioxidant and micronutrient supplementation on the sperm parameters of male patients with idiopathic infertility: An updated literature review

09 Jun 2020

Infertility is a problem faced by 5-10 percent of couples, with male factor accounting for up to 47 percent of cases. [Int J Androl 1987;7(Suppl):1]. There are many causes for male infertility but up to 15 percent of cases are idiopathic in nature. These cases may be related to unregulated excessive oxidative stress, which may impair spermatogenesis; hence, arousing research into the role of antioxidant supplementation in improving the sperm parameters.

Denosumab: A critical aspect of metastatic prostate cancer treatment

Prof. Bertrand Tombal, Assoc Prof. Edmund Chiong, 18 May 2022

Men with metastatic prostate cancer (mPC) have an elevated risk of skeletal complications either due to bone metastases (skeletal-related events [SREs]), or from osteoporosis induced by androgen deprivation therapy (ADT). Two key opinion leaders recently shared their perspectives on bone complications in mPC as well as the use of bone-targeted agents (BTAs) such as denosumab (Xgeva) to reduce the risk of bone complications.

Professor Bertrand Tombal

Professor of Urology

Cliniques universitaires Saint-Luc & Université catholique de Louvain

Brussels, Belgium

Associate Professor Edmund Chiong

Head, Department of Urology

National University Hospital, Singapore

Optimizing metastatic hormone-sensitive prostate cancer treatment in advanced prostate cancer

Assoc Prof. Darren Poon, Assoc Prof. Edmund Chiong, 14 Jan 2021

Metastatic hormone-sensitive prostate cancer (mHSPC) refers to the condition whereby patients have metastatic prostate cancer and no prior hormonal therapy or androgen deprivation therapy (ADT). Typically, patients with mHSPC have been treated with ADT alone, following which, the overwhelming majority develop castration resistance over time and head towards eventual mortality. In recent years, the publication of various landmark trials has prompted dramatic changes in the mHSPC treatment landscape, and had favourably impacted overall survival (OS) in these patients. At a recent webinar, A/Prof Darren Poon, Honorary Consultant in Clinical Oncology, Hong Kong Sanatorium & Hospital, and Honorary Clinical Associate Professor, Department of Clinical Oncology, The Chinese University of Hong Kong, reviewed treatment options in mHSPC, while A/Prof Edmund Chiong, Head and Senior Consultant, Department of Urology, National University Hospital, Singapore, presented a case which was discussed by an esteemed panel of experts. This webinar was jointly organized by the Singapore Society of Oncology and the Singapore Urological Association, and supported by Astellas.